Literature DB >> 14614325

Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines.

Lan Yan1, Sharyl J Nass, Dawn Smith, William G Nelson, James G Herman, Nancy E Davidson.   

Abstract

Recent studies have shown that changes in epigenetic regulation, such as DNA methylation and histone acetylation, are associated with silencing of the estrogen receptor a (ER) gene in ER-negative human breast cancer cells. Treatment of these cells with the general DNMT inhibitor, 5-aza-2'deoxycytidine, led to reactivation of functional ER protein. This study addresses the hypothesis that specific inhibition of the maintenance DNA methyltransferase, DNMT1, by antisense oligonucleotides (DNMT1 ASO) is sufficient to re-express the ER gene in ER-negative human breast cancer cell lines. MDA-MB-231 and Hs578t cells were transfected with 100 nM and 150 nM DNMT1 ASO respectively for three consecutive days and evidence of DNMT1 downregulation and functional ER re-expression was sought. Significant growth reduction was observed within 48 hr and persisted after 96 hr. DNMT1 expression was blocked after exposure to DNMT1 ASO as detected by RT-PCR, Western blot and enzymatic assay whereas a mutant DNMT1 ASO had little effect. This was associated with enhanced ER mRNA and protein expression and restoration of estrogen responsiveness in MDA-MB-231 cells as demonstrated by the ability of the induced ER protein to elicit ERE-regulated reporter activity from a luciferase reporter construct. Methylation specific PCR showed that the ER CpG island was minimally demethylated, suggesting that other epigenetic events, introduced by specific DNMT1 inhibition, might also be involved in ER re-expression. Our results suggest that specific inhibition of DNMT1 expression alone is sufficient to re-express ERa in human breast cancer cell lines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14614325     DOI: 10.4161/cbt.2.5.469

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  38 in total

Review 1.  Intrinsic and Extrinsic Factors Governing the Transcriptional Regulation of ESR1.

Authors:  David K Lung; Rebecca M Reese; Elaine T Alarid
Journal:  Horm Cancer       Date:  2020-06-26       Impact factor: 3.869

Review 2.  Aberrant DNA methylation in human cancers.

Authors:  Wen Li; Bi-Feng Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-12-13

Review 3.  Cancer epigenetics: above and beyond.

Authors:  Mariana Brait; David Sidransky
Journal:  Toxicol Mech Methods       Date:  2011-05       Impact factor: 2.987

Review 4.  Quantitative assessment of DNA methylation: Potential applications for disease diagnosis, classification, and prognosis in clinical settings.

Authors:  Romulo Martin Brena; Tim Hui-Ming Huang; Christoph Plass
Journal:  J Mol Med (Berl)       Date:  2006-01-17       Impact factor: 4.599

Review 5.  Epigenetic mechanisms of regulation of Foxp3 expression.

Authors:  Girdhari Lal; Jonathan S Bromberg
Journal:  Blood       Date:  2009-07-29       Impact factor: 22.113

Review 6.  Role of epigenetic modifications in luminal breast cancer.

Authors:  Hany A Abdel-Hafiz; Kathryn B Horwitz
Journal:  Epigenomics       Date:  2015-02-17       Impact factor: 4.778

7.  p53 Binds to estrogen receptor 1 promoter in human breast cancer cells.

Authors:  Mozhgan Rasti; Rita Arabsolghar; Zahed Khatooni; Zoherh Mostafavi-Pour
Journal:  Pathol Oncol Res       Date:  2011-06-08       Impact factor: 3.201

Review 8.  Epigenomics and breast cancer.

Authors:  Pang-Kuo Lo; Saraswati Sukumar
Journal:  Pharmacogenomics       Date:  2008-12       Impact factor: 2.533

9.  Mutant p53 binds to estrogen receptor negative promoter via DNMT1 and HDAC1 in MDA-MB-468 breast cancer cells.

Authors:  Rita Arabsolghar; Tayebeh Azimi; Mozhgan Rasti
Journal:  Mol Biol Rep       Date:  2012-12-15       Impact factor: 2.316

10.  FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance.

Authors:  J Millour; D Constantinidou; A V Stavropoulou; M S C Wilson; S S Myatt; J M-M Kwok; K Sivanandan; R C Coombes; R H Medema; J Hartman; A E Lykkesfeldt; E W-F Lam
Journal:  Oncogene       Date:  2010-03-08       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.